Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Regulation FD DisclosureItem 7.01
Regulation FD Disclosure.
On June 23, 2018, Array BioPharma Inc. issued a press release announcing additional results of encorafenib, binimetinib and cetuximab in patients with BRAF-mutant colorectal cancer that were presented at the ESMO 20th World Congress on Gastrointestinal Cancer. A copy of the press release is included as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
|
Item 7.01 |
Financial Statements and Exhibits. |
(d)Exhibits
|
ExhibitNo. |
Description |
|
99.1 |
Press release dated June 23, 2018.
|
ARRAY BIOPHARMA INC ExhibitEX-99.1 2 arraybeaconesmogi62218fi.htm EXHIBIT 99.1 arraybeaconesmogi62218fi News Release Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib,…To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
